Fortress Biotech, Inc. Business Combination, Consideration Transferred
Fortress Biotech, Inc. (FBIO) reported Business Combination, Consideration Transferred of $22.87 million for the 12-month period ending 2017-12-31, per its 10-K filed 2018-03-16.
Discontinued › Notes › Business Combination, Asset Acquisition, Transaction between Entities under Common Control, and Joint Venture Formation
us-gaap:BusinessCombinationConsiderationTransferred1 · last filed 2018-03-16
- Fortress Biotech, Inc. business combination, consideration transferred for the quarter ending 2017-12-31 was $22.68M, a 0.84% decline year-over-year.
- Fortress Biotech, Inc. business combination, consideration transferred for the quarter ending 2017-03-31 was $22.87M.
- Fortress Biotech, Inc. business combination, consideration transferred for the quarter ending 2016-12-31 was $22.87M.
- Fortress Biotech, Inc. business combination, consideration transferred for fiscal 2017 was $22.87M, a 0.00% change from fiscal 2016.
- Fortress Biotech, Inc. business combination, consideration transferred for fiscal 2016 was $22.87M.
| Period end | Business Combination, Consideration Transferred 3 month | Business Combination, Consideration Transferred 6 month | Business Combination, Consideration Transferred 9 month | Business Combination, Consideration Transferred 9 month as first filed | Business Combination, Consideration Transferred 12 month |
|---|---|---|---|---|---|
| 2017-12-31 | $22.68M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-16 | $22.87M 10-K · filed 2018-03-16 | |||
| 2017-09-30 | $192.00K 10-Q · filed 2017-11-09 | ||||
| 2017-03-31 | $22.87M 10-Q · filed 2017-05-10 | $45.74M derived: sum of 2 quarters · filed 2017-05-10 | |||
| 2016-12-31 | $22.87M derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-16 | $22.87M 10-K · filed 2017-03-16 | |||
| 2016-09-30 | $0.00 10-Q · filed 2017-11-09 | $22.87M 10-Q · filed 2016-11-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ALX ONCOLOGY HOLDINGS INC (ALXO) | United States | $0.187B | -3.52 |
| PepGen Inc. (PEPG) | United States | $0.186B | -1.73 |
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| Zentalis Pharmaceuticals, Inc. (ZNTL) | United States | $0.196B | -2.48 |
| ORAMED PHARMACEUTICALS INC. (ORMP) | $0.199B | 1.13 | |
| Nkarta, Inc. (NKTX) | United States | $0.205B | -1.73 |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | United States | $0.166B | -1.34 |
| Minerva Neurosciences, Inc. (NERV) | United States | $0.165B | -0.66 |
| ADC Therapeutics SA (ADCT) | $0.163B | -1.39 |